NCT00874146Unknown不适用
Retrospective Study of the Level of HER2-neu Gene Amplification as Predictive Factor of Response in Patients With HER2-positive Advanced Breast Cancer Treated With Trastuzumab Containing Regimens.
Istituto Clinico Humanitas1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2009年3月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Association of tumor cytogenetic paremeters with TTP and OS.
研究概览
简要总结
Primary objective of the study is to evaluate the correlation between level of HER2-neu gene amplification evalued by dual-color Fluorescent in-situ hybridization (FISH) test and time to progression (TTP) in patients with HER2-positive advanced breast cancer treated with trastuzumab-containing regimens.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •HER2-positive breast cancer Trastuzumab-containing regimen delivered for advanced disease Tumor sample available at Pathology Archive
排除标准
- •HER2-negative advanced breast cancer Pretreatment with trastuzumab
结局指标
主要结局
Association of tumor cytogenetic paremeters with TTP and OS.
时间窗: one year
次要结局
- Association of cytogenetic parameters evalued by FISH test and patients' characteristics.(one year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCRRecurrent or Metastatic Breast CancerNCT03947736Chinese Academy of Medical Sciences200
已完成
不适用
Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer PatientsBreast Cancer, HER2NCT05203458AstraZeneca3,136
已完成
不适用
Safety and Efficacy Assessment of Diagnostic Microprobe (inPROBE) in Women at High Risk of Breast Cancer (Part I Study)Breast CancerNCT05415943SDS Optic S.A.18
招募中
不适用
A study for assessment of HER2 status using Gene-Protein Assay (GPA) in metastatic colorectal cancercolorectal cancerJPRN-UMIN000039751ational Cancer Center150
已完成
2 期
A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast CancerBreast CancerNCT00885755Hoffmann-La Roche33